CA2876469A1 - Modeles de souris transgeniques destines au mc4r - Google Patents

Modeles de souris transgeniques destines au mc4r Download PDF

Info

Publication number: CA2876469A1
Authority: CA; Canada
Prior art keywords: transgene; transgenic non; protein; human; hmc4r
Prior art date: 2012-06-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2876469

Other languages

English (en)

Inventor

Michel Bouvier

Patricia Rene

Benjamin TURGEON

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Universite de Montreal

Original Assignee

Universite de Montreal

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-14

Filing date

2013-06-14

Publication date

2013-12-19

2013-06-14 Application filed by Universite de Montreal filed Critical Universite de Montreal

2013-12-19 Publication of CA2876469A1 publication Critical patent/CA2876469A1/fr

Status Abandoned legal-status Critical Current

Links

238000011830 transgenic mouse model Methods 0.000 title description 25
108700019146 Transgenes Proteins 0.000 claims abstract description 269
230000009261 transgenic effect Effects 0.000 claims abstract description 228
108090000623 proteins and genes Proteins 0.000 claims abstract description 174
230000008685 targeting Effects 0.000 claims abstract description 134
208000008589 Obesity Diseases 0.000 claims abstract description 103
102000004169 proteins and genes Human genes 0.000 claims abstract description 87
241001465754 Metazoa Species 0.000 claims abstract description 81
235000020824 obesity Nutrition 0.000 claims abstract description 81
238000000034 method Methods 0.000 claims abstract description 57
238000012216 screening Methods 0.000 claims abstract description 21
108010008364 Melanocortins Proteins 0.000 claims abstract description 19
239000002865 melanocortin Substances 0.000 claims abstract description 19
230000000717 retained effect Effects 0.000 claims abstract description 11
101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 claims description 161
102000057094 human MC4R Human genes 0.000 claims description 155
210000004027 cell Anatomy 0.000 claims description 136
230000035772 mutation Effects 0.000 claims description 125
101150110867 MC4R gene Proteins 0.000 claims description 89
210000001519 tissue Anatomy 0.000 claims description 77
230000014509 gene expression Effects 0.000 claims description 72
210000004962 mammalian cell Anatomy 0.000 claims description 57
238000012360 testing method Methods 0.000 claims description 43
150000001875 compounds Chemical class 0.000 claims description 42
102000005962 receptors Human genes 0.000 claims description 39
108020003175 receptors Proteins 0.000 claims description 39
108091005957 yellow fluorescent proteins Proteins 0.000 claims description 37
108091006047 fluorescent proteins Proteins 0.000 claims description 36
102000034287 fluorescent proteins Human genes 0.000 claims description 36
239000003550 marker Substances 0.000 claims description 35
239000003795 chemical substances by application Substances 0.000 claims description 32
238000002744 homologous recombination Methods 0.000 claims description 31
230000006801 homologous recombination Effects 0.000 claims description 31
238000010172 mouse model Methods 0.000 claims description 30
YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 claims description 28
241000545067 Venus Species 0.000 claims description 28
125000003275 alpha amino acid group Chemical group 0.000 claims description 27
229930193140 Neomycin Natural products 0.000 claims description 23
229960004927 neomycin Drugs 0.000 claims description 23
241000283984 Rodentia Species 0.000 claims description 21
108010006519 Molecular Chaperones Proteins 0.000 claims description 20
230000000144 pharmacologic effect Effects 0.000 claims description 20
230000007781 signaling event Effects 0.000 claims description 20
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 17
108010052160 Site-specific recombinase Proteins 0.000 claims description 17
239000004475 Arginine Substances 0.000 claims description 13
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 13
239000005090 green fluorescent protein Substances 0.000 claims description 13
239000003446 ligand Substances 0.000 claims description 13
108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 11
102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 11
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 11
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 11
208000030159 metabolic disease Diseases 0.000 claims description 11
230000037213 diet Effects 0.000 claims description 10
235000005911 diet Nutrition 0.000 claims description 10
238000003780 insertion Methods 0.000 claims description 10
230000037431 insertion Effects 0.000 claims description 10
108091005948 blue fluorescent proteins Proteins 0.000 claims description 9
210000000349 chromosome Anatomy 0.000 claims description 9
108010082025 cyan fluorescent protein Proteins 0.000 claims description 9
206010022000 influenza Diseases 0.000 claims description 9
208000014258 obesity due to melanocortin 4 receptor deficiency Diseases 0.000 claims description 9
108010054624 red fluorescent protein Proteins 0.000 claims description 9
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 8
230000012010 growth Effects 0.000 claims description 6
230000002829 reductive effect Effects 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
208000024891 symptom Diseases 0.000 claims description 5
206010020710 Hyperphagia Diseases 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
102100023724 Melanocortin receptor 4 Human genes 0.000 claims 5
230000007812 deficiency Effects 0.000 claims 1
238000011160 research Methods 0.000 abstract description 4
108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 204
102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 200
229920001184 polypeptide Polymers 0.000 description 106
102000004196 processed proteins & peptides Human genes 0.000 description 106
108090000765 processed proteins & peptides Proteins 0.000 description 106
241000699670 Mus sp. Species 0.000 description 62
108700028369 Alleles Proteins 0.000 description 39
108020004414 DNA Proteins 0.000 description 32
150000007523 nucleic acids Chemical class 0.000 description 30
241000699666 Mus <mouse, genus> Species 0.000 description 28
108091026890 Coding region Proteins 0.000 description 26
239000012634 fragment Substances 0.000 description 26
238000003752 polymerase chain reaction Methods 0.000 description 26
235000018102 proteins Nutrition 0.000 description 26
108091033319 polynucleotide Proteins 0.000 description 24
102000040430 polynucleotide Human genes 0.000 description 24
239000002157 polynucleotide Substances 0.000 description 24
102000039446 nucleic acids Human genes 0.000 description 23
108020004707 nucleic acids Proteins 0.000 description 23
239000002773 nucleotide Substances 0.000 description 23
125000003729 nucleotide group Chemical group 0.000 description 23
108091028043 Nucleic acid sequence Proteins 0.000 description 22
239000013598 vector Substances 0.000 description 22
241001529936 Murinae Species 0.000 description 19
238000002105 Southern blotting Methods 0.000 description 19
230000002759 chromosomal effect Effects 0.000 description 18
238000010363 gene targeting Methods 0.000 description 17
101100129530 Homo sapiens MC4R gene Proteins 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 16
238000009396 hybridization Methods 0.000 description 16
230000000295 complement effect Effects 0.000 description 15
230000006870 function Effects 0.000 description 15
230000010354 integration Effects 0.000 description 15
230000006798 recombination Effects 0.000 description 15
238000005215 recombination Methods 0.000 description 15
239000000523 sample Substances 0.000 description 15
101100239628 Danio rerio myca gene Proteins 0.000 description 14
101150039798 MYC gene Proteins 0.000 description 14
101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 14
229940024606 amino acid Drugs 0.000 description 14
235000012631 food intake Nutrition 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 12
239000003623 enhancer Substances 0.000 description 12
239000000047 product Substances 0.000 description 12
230000001105 regulatory effect Effects 0.000 description 12
241000699660 Mus musculus Species 0.000 description 10
238000010586 diagram Methods 0.000 description 10
230000037406 food intake Effects 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
230000037396 body weight Effects 0.000 description 9
238000012512 characterization method Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
230000000694 effects Effects 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
108091008146 restriction endonucleases Proteins 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
238000012546 transfer Methods 0.000 description 9
241000282412 Homo Species 0.000 description 8
210000002459 blastocyst Anatomy 0.000 description 8
238000012217 deletion Methods 0.000 description 8
230000037430 deletion Effects 0.000 description 8
-1 e.g. Proteins 0.000 description 8
239000003925 fat Substances 0.000 description 8
230000002441 reversible effect Effects 0.000 description 8
101710154606 Hemagglutinin Proteins 0.000 description 7
101710093908 Outer capsid protein VP4 Proteins 0.000 description 7
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 7
101710176177 Protein A56 Proteins 0.000 description 7
238000013459 approach Methods 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
238000004520 electroporation Methods 0.000 description 7
239000000185 hemagglutinin Substances 0.000 description 7
238000005259 measurement Methods 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
208000016261 weight loss Diseases 0.000 description 7
102000005431 Molecular Chaperones Human genes 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002372 labelling Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
101150091879 neo gene Proteins 0.000 description 6
101100129532 Mus musculus Mc4r gene Proteins 0.000 description 5
108010091086 Recombinases Proteins 0.000 description 5
102000018120 Recombinases Human genes 0.000 description 5
101150003725 TK gene Proteins 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000027455 binding Effects 0.000 description 5
238000009395 breeding Methods 0.000 description 5
230000001488 breeding effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
239000003814 drug Substances 0.000 description 5
210000004602 germ cell Anatomy 0.000 description 5
210000005260 human cell Anatomy 0.000 description 5
238000003364 immunohistochemistry Methods 0.000 description 5
238000011065 in-situ storage Methods 0.000 description 5
230000004807 localization Effects 0.000 description 5
230000031852 maintenance of location in cell Effects 0.000 description 5
238000000520 microinjection Methods 0.000 description 5
210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
230000004580 weight loss Effects 0.000 description 5
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
241001045988 Neogene Species 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
238000007681 bariatric surgery Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000005540 biological transmission Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
210000001671 embryonic stem cell Anatomy 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
238000001638 lipofection Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
VDYQCGZDQGNKFI-UHFFFAOYSA-N methyl 2-(4-azidophenyl)ethanimidate;hydrochloride Chemical compound Cl.COC(=N)CC1=CC=C(N=[N+]=[N-])C=C1 VDYQCGZDQGNKFI-UHFFFAOYSA-N 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000012846 protein folding Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000003908 quality control method Methods 0.000 description 4
241000894007 species Species 0.000 description 4
229940124598 therapeutic candidate Drugs 0.000 description 4
239000004474 valine Substances 0.000 description 4
238000012800 visualization Methods 0.000 description 4
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
241000288906 Primates Species 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000019439 energy homeostasis Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
208000037493 inherited obesity Diseases 0.000 description 3
238000011813 knockout mouse model Methods 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000001161 mammalian embryo Anatomy 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000001608 teratocarcinoma Diseases 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
230000004584 weight gain Effects 0.000 description 3
235000019786 weight gain Nutrition 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
108010051219 Cre recombinase Proteins 0.000 description 2
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
241000233866 Fungi Species 0.000 description 2
208000036391 Genetic obesity Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 2
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
210000000579 abdominal fat Anatomy 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
238000010171 animal model Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
239000012620 biological material Substances 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
230000004097 bone metabolism Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
235000021316 daily nutritional intake Nutrition 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
101150106093 gpt gene Proteins 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
229960000951 mycophenolic acid Drugs 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000012301 transgenic model Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
208000007683 Pediatric Obesity Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
102100037204 Sal-like protein 1 Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
210000004490 abdominal subcutaneous fat Anatomy 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
150000001484 arginines Chemical class 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000011259 co-electroporation Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
108700023159 delta Opioid Receptors Proteins 0.000 description 1
102000048124 delta Opioid Receptors Human genes 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
238000013427 histology analysis Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
208000001022 morbid obesity Diseases 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000001216 nucleic acid method Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
108010030587 rat melanocortin receptor type 4 Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
238000010187 selection method Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000007019 strand scission Effects 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
238000010809 targeting technique Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Environmental Sciences (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biophysics (AREA)
Biodiversity & Conservation Biology (AREA)
Animal Husbandry (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Public Health (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA 2876469 2012-06-14 2013-06-14 Modeles de souris transgeniques destines au mc4r Abandoned CA2876469A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261659739P	2012-06-14	2012-06-14
US61/659,739		2012-06-14
PCT/CA2013/050457 WO2013185239A1 (fr)	2012-06-14	2013-06-14	Modèles de souris transgéniques destinés au mc4r

Publications (1)

Publication Number	Publication Date
CA2876469A1 true CA2876469A1 (fr)	2013-12-19

Family

ID=49757378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2876469 Abandoned CA2876469A1 (fr)	2012-06-14	2013-06-14	Modeles de souris transgeniques destines au mc4r

Country Status (3)

Country	Link
US (2)	US20150150224A1 (fr)
CA (1)	CA2876469A1 (fr)
WO (1)	WO2013185239A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11730828B2 (en) *	2017-02-07	2023-08-22	The Regents Of The University Of California	Gene therapy for haploinsufficiency
JP7297214B2 (ja) *	2017-09-28	2023-06-26	国立大学法人京都大学	魚類および魚類の生産方法
CN117070521A (zh) *	2023-06-25	2023-11-17	湖北省农业科学院畜牧兽医研究所	一种山羊mc4r缺陷型突变体及其应用
WO2025217738A1 (fr) *	2024-04-19	2025-10-23	Congruence Therapeutics Inc.	Modèle de souris obèse génétiquement modifié

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5464764A (en) *	1989-08-22	1995-11-07	University Of Utah Research Foundation	Positive-negative selection methods and vectors
US5932779A (en) *	1996-06-10	1999-08-03	Millennium Pharmaceuticals, Inc.	Screening methods for compounds useful in the regulation of body weight
EP1241934A4 (fr) *	1999-11-12	2005-04-27	Merck & Co Inc	Cellules deficientes en recepteurs 4 de melanocortine, animaux transgeniques non humains et procedes de selection de composes qui regulent le poids corporel
US7321074B1 (en) *	1999-11-12	2008-01-22	Merck & Co., Inc.	Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight
US20030153044A1 (en) *	2001-05-14	2003-08-14	Monika Liljedahl	Tissues or organs for use in xenotransplantation
US20070021433A1 (en) *	2005-06-03	2007-01-25	Jian-Qiang Fan	Pharmacological chaperones for treating obesity
US20080181877A1 (en) *	2006-03-22	2008-07-31	Leangene Ab, C/O Cit Ekonomiservice Ab	Method For Monitoring the Effect of Compounds on Foxc2 Expression
US8609927B2 (en) *	2009-05-28	2013-12-17	Trustees Of Dartmouth College	Caveolin 1-reporter protein knock-in mouse

2013
- 2013-06-14 CA CA 2876469 patent/CA2876469A1/fr not_active Abandoned
- 2013-06-14 US US14/407,779 patent/US20150150224A1/en not_active Abandoned
- 2013-06-14 WO PCT/CA2013/050457 patent/WO2013185239A1/fr not_active Ceased
2016
- 2016-08-12 US US15/235,638 patent/US20160345553A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2013185239A1 (fr)	2013-12-19
US20160345553A1 (en)	2016-12-01
US20150150224A1 (en)	2015-06-04

Legal Events

Date	Code	Title	Description
2019-07-27	FZDE	Discontinued	Effective date: 20190614

Publication	Publication Date	Title
US8524975B2 (en)	2013-09-03	Method of predicting a behavior of one or more drugs
McCright et al.	2006	Generation of new Notch2 mutant alleles
AU2002248977A1 (en)	2003-04-17	Transgenic non-human animals for pharmacological and toxicological studies
JP4997544B2 (ja)	2012-08-08	ヒトチトクロームｐ４５０遺伝子（クラスター）を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物
US20200359610A1 (en)	2020-11-19	Humanized transgenic animal
US20160345553A1 (en)	2016-12-01	Transgenic mouse models for mc4r
JP5075641B2 (ja)	2012-11-21	遺伝子改変動物およびその用途
CN112292030A (zh)	2021-01-29	进行性骨化性纤维发育不良的啮齿类动物模型
JP2006506968A (ja)	2006-03-02	アグーチ関連蛋白質欠損細胞、非ヒトトランスジェニック動物及びエネルギー代謝を調節する化合物の選択方法
WO2011055366A1 (fr)	2011-05-12	Animal non humain à gène knock-out conditionnel de mo-1 et utilisations de celui-ci
WO2009142724A2 (fr)	2009-11-26	Souris transgéniques gpr101 inédites et leurs procédés d'utilisation
US20220217956A1 (en)	2022-07-14	Rodent Model Of Increased Bone Mineral Density
US20090007283A1 (en)	2009-01-01	Transgenic Rodents Selectively Expressing Human B1 Bradykinin Receptor Protein